Company Overview

Medial EarlySign helps healthcare systems with early detection and prevention of high-burden diseases. Our outcome-focused software solutions (AlgoMarkers™) find subtle, early signs of high-risk patient trajectories in existing lab results and ordinary EHR data already collected in the course of routine care. EarlySign AlgoMarkers help clients identify patients at high risk for conditions such as lower GI disorders, prediabetic progression to diabetes, downstream diabetic complications, first coronary artery disease (CAD) and CAD equivalent events, and chronic kidney disease (CKD).

EarlySign's validated clinical risk predictors are rooted in deep expertise in Machine Learning. They provide clients the ability to identify early opportunities for prevention, intervention, and enhanced care management of high-burden, prevalent diseases. Utilizing EarlySign AlgoMarkers, client results may include lower cost of care and improved health of populations.

Leverage Existing Data for Higher Quality Care

As healthcare systems transition from volume- to value-based care, they can leverage existing patient EHR data with our clinical risk predictors to implement preventive, personalized care plans. Our AlgoMarkers™ support outcome-focused care delivery, helping clients concentrate on preventing or delaying the onset of high-burden diseases, downstream complications, and their associated costs.

Validated Solutions, Peer-Reviewed Publications

Medial EarlySign's solutions are being implemented in clinical practice at leading healthcare systems in the US, Israel, and Europe.

AlgoMarker™ clinical risk predictors are validated via retrospective data studies on diverse US, UK, and Israeli populations at sites that include more than 20 million patients. The results of our work are regularly published in peer-reviewed clinical journals. Large scale, high quality, scientifically designed clinical data studies are an integral part of our process for developing and validating models.



Full Integration in Clinical Workflow

The success of any clinical predictor is predicated on its successful integration into the clinical care workflow. Its implementation must support and enhance rather than disrupt or change existing clinical practice. Comprised of physicians and highly experienced implementation experts, our customer success team listens to each client to understand their existing workflows and then develops a customized plan for each selected AlgoMarker™. We work quickly to deploy a "tailored" solution with minimal disruption that is easy for care-givers to adopt.

Our solutions' IT footprint is small, enabling a low-touch integration with client IT systems that can often be completed in weeks.

MKG-14-01-27 Rev. B

Medial EarlySign's Clinical Risk Predictors (AlgoMarkers™)

Our computational software solutions identify patients at high risk for progressing to various high-burden diseases and chronic medical conditions, for whom further evaluation and heightened awareness, per current standards of care and guidelines, are warranted[1].

LGI-Flag AlgoMarker™

Identifies individuals at high risk of having lower GI disorders using complete blood count (CBC) test results, age, and gender.

Prediabetes to Diabetes AlgoMarker™

Identifies prediabetic patients at high risk for progressing to diabetes within the next 12 months using routine blood test results, age, gender and BMI.



Diabetes to CKD AlgoMarker™

Identifies Type 2 Diabetic (T2D) patients at high risk for progressing to chronic kidney disease (CKD) stages 2-4 within 3 years using basic demographic data, routine lab results, diagnostic codes, and drug information.

Hypertension to CKD AlgoMarker™

Identifies hypertensive ('HTN') patients at high risk for progressing to CKD stages 2-4 within 3 years using basic demographic data, routine lab results, diagnostic codes, and drug information.

Diabetes to First CAD event AlgoMarker™

Identifies T2D patients at high risk for having a first coronary artery disease (CAD) event and CAD equivalents within the next three (3) years using basic demographic data, routine lab results, diagnostic codes, drugs, and smoking history.

First CAD event AlgoMarker™

Identifies patients in the general population at high risk for having a first CAD event and CAD equivalents within the next three (3) years using basic demographic data, routine lab results, diagnostic codes, drugs, and smoking history.

---

[1] Each AlgoMarker™ is a relative risk indicator that is intended for use by healthcare systems and their affiliates to evaluate patient's risk in the context of patient's overall health and medical history, and it is not intended for use in the diagnosis or screening of the particular medical condition it addresses.

Note: for detailed information about each AlgoMarker, contact us.

MKG-14-01-27 Rev. B

Medial EarlySign

T: 617-916-9144 | solutions@earlysign.com | www.earlysign.com